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NC-ND license (http://creativecommoSummary Objective: The objective of the study was to assess the patterns of central cervi-
cal lymph node metastasis (CLNM) and evaluate the prophylactic central lymph node dissection
(CLND) in papillary thyroid carcinoma (PTC) patients without clinical positive lymph nodes.
Methods: We retrospectively reviewed 1555 patients with PTC between 2003 and 2008. Lymph
node metastatic risk factors and the pattern of lymph node metastasis in PTC were studied us-
ing multivariate analysis.
Results: Male patients, aged  45 years, the presence of extrathyroidal extension, and a pri-
mary tumor size > 10 mm were identified as risk factors for CLNM with odds ratios of 2.089,
2.417, 1.534, and 3.079, respectively. Among 1555 patients, 97 cases (6.24%) had transient hy-
poparathyroidism, and only two patients (0.13%) had permanent hypoparathyroidism. Recur-
rent laryngeal nerve injury after thyroidectomy occurred in 14 patients (0.9%). In this group,
nine cases were transient injury and the remaining five were permanent. During the period
of follow-up, ranging from 5 years to 10 years, 18 patients (1.16%) were found with locoregio-
nal recurrence.
Conclusion: Taken together, in terms of the high incidence rate of CLNM in cN0 PTC patients,
we believe that routine prophylactic CLND is optimal for clinically negative PTC patients, dur-
ing their first treatment, especially for those with risk factors for CLNM.
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Papillary thyroid carcinoma (PTC) is the most common
pathological type of thyroid malignancy, and exhibits a slow
growth rate and good prognosis.1 However, cervical
lymphatic metastasis occurs in approximately 40e90% of
PTC patients.2 Cervical lymph node metastasis (CLNM) does
not affect the overall prognosis of PTC but enhances the
regional recurrence that is often life threatening. There-
fore, local lymph node recurrence, after PTC operation, is a
major issue that concerns clinicians.
Many studies have been performed to evaluate the risk
factors of CLNM, however, those studies included both the
patients with clinically negative (cN0) and clinically posi-
tive central lymph node. It is rare for studies to focus on the
evaluation of risk factors as a predictor for CLNM only in
cN0 patients. Therefore, identification of risk factors
associated with CLNM may help surgeons to choose appro-
priate surgical strategies for cN0 PTC patients.
Since thyroid and neck lymphatic drainage patterns are
relatively fixed, the pattern of metastatic lymph nodes is
relatively predictable. Central lymph node is the most
common site of cancer metastasis in the majority of PTC
patients.3,4 According to current American Thyroid Associ-
ation recommendations, most surgeons would undertake
central lymph node dissection (CLND) for T3 or T4 tumors in
high-risk patients, but avoid CLND for T1 or T2 tumors in
low-risk patients. However, the debate regarding prophy-
lactic CLND for patients with cN0 central lymph node re-
mains unresolved today. To this end, the objective of this
study was to assess the patterns of central cervical lymph
node metastasis and evaluate the value of prophylactic
CLND for treatment of cN0 PTC patients.
2. Materials and methods
2.1. Patients
This study was approved by the Ethical Committee of The
First Hospital of the Jilin University, Changchun, China. A
total of 1555 cN0 patients with PTC were treated at the
Department of Thyroid Surgery, The First Hospital of the
Jilin University between July 2003 and July 2008. All pa-
tients recruited in the study met the following criteria: (1)
their information was found in the hospital database; (2)
they had a postoperative pathological diagnosis of PTC; and
(3) no clinically positive central lymph node was detected
preoperatively with either ultrasound or palpation. Patients
were excluded from the study if they had a history of neck
radiotherapy, distant metastasis, or previous thyroid
surgery.
2.2. Surgical treatment
Clinical diagnosis was initially made with examination of
ultrasound and fine needle aspiration. Because the results
of pathologic examination of the frozen sections (FS)
during surgery could guide the extent of the surgical
operation in PTC patients, the FS was applied to all cN0
patients. To reduce the recurrence of the PTC,lobectomy plus ipsilateral CLND was performed as the
initial surgical therapy for PTC patients with malignant
lesions < 1 cm that were limited to a single lobe. If
malignant lesions in both lobes of the thyroid were
confirmed in FS, or the diameter of the malignant lesion
was larger than 1 cm, a total thyroidectomy plus bilateral
CLND was performed.2.3. Perioperative management and follow-up
The levels of parathyroid hormone (PTH), calcium, phos-
phorus, and ionized calcium of all patients were examined
preoperatively and also measured routinely at 2 days after
surgery. Postoperative hypoparathyroidism is defined as any
hypocalcemic symptom with a decreased PTH level (<
15 pg/mL) and decreased serum calcium level (< 8.0 mg/
dL) or ionized calcium (< 1.00 mmol/L) level, with an
elevated phosphorus level (< 5.0 mg/dL). Permanent hy-
poparathyroidism is defined as a case of decreased PTH
level that requires compensation with medication > 12
months after surgery. Transient hypoparathyroidism is
defined as the absence of hypocalcemic symptoms and
decreased PTH level if the medication was stopped within
the 12-month period. Calcium and vitamin D were admin-
istered, according to the laboratory findings and hypocal-
cemic symptoms.
Before surgery and on Day 1 after surgery, laryngoscopy
(either indirect or direct video laryngoscopy) was manda-
tory. An additional examination was scheduled at 1 month,
2 months, 4 months, 6 months, and 12 months after surgery
in patients with recurrent laryngeal nerve paresis, or until
the vocal cord function was recovered. Vocal cord paresis
for > 12 months after surgery was regarded as permanent
palsy.
Thyroid stimulating hormone-suppressive hormonal
therapy was applied to all postoperative patients and
radioactive iodine therapy was used in cases with gross
extrathyroidal extension of the tumor regardless of tumor
size, primary tumor size > 4 cm, or 1e4 cm thyroid cancers
confined to the thyroid who have documented lymph node
metastases, or other higher risk features. Postoperative
physical examinations were performed every 3e6 months.
During the period of follow-up, all patients underwent ul-
trasound examinations of the neck as well as a thyroid
function test. Patients with total thyroidectomy plus
bilateral CLND were monitored with a thyroglobulin exam-
ination and Iodine-131 scan. We took both the central and
lateral compartment into account as the local regional
recurrence. A follow-up between 5 years and 10 years
postsurgery was achieved for all patients.2.4. Statistical analysis
Statistical analyses were performed using c2 tests. Odds
ratios and 95% confidence intervals for relationships be-
tween each variable and lymph node metastasis (yes or no)
were calculated using binary logistic regression. SPSS
version 18.0 software (SPSS Inc., Chicago, IL, USA) was used
for data processing and bilateral inspection; p < 0.05 was
considered statistically significant.
Table 2 Multivariate logistic regression for CLNM.
p Odds ratio
Male Gender < 0.001 2.089
Age less than 45 y < 0.001 2.417
Multifocal 0.083 1.318
Extrathyroidal extension 0.001 1.534
Maximum tumor diameter >
10 mm
0.000 3.079
Bilateral carcinoma 0.184 1.251
Combined with nodular goiter 0.228 0.872
Combined with adenoma 0.23 0.789
CLNM Z cervical lymph node metastasis.
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3.1. Patient characteristics
A total of 1555 cN0 PTC patients aged from 14e85 years
(mean 43.25  10.38 years) were enrolled. The male-to-
female ratio was 1:5.2 (267 males 267 and 1388 females).
The largest tumor was 8.0 cm, and the smallest tumor was
< 0.1 cm. The mean number of tumors was 1.62 and ranged
from one tumor to eight tumors. Bilateral tumors were
found in 504 cases and unilateral tumors in 1051 cases. The
rate of CLNM was 45.85% (713 out of 1555 cases). The mean
number of central lymph nodes harvested was 5.46 (ranging
from 1 to 46). We found nodular goiters in 788 cases, thy-
roid adenoma in 104 cases, and Hashimoto’s thyroiditis in
607 cases.
3.2. Risk factors of CLNM
In an independent variable c2 test, variables including
young age (i.e., < 45 years of age), male gender, extra-
thyroidal extension (ETE), multifocal tumors, bilateral tu-
mors, and a tumor size > 1 cm were significantly associated
with CLNM (Table 1). But, Hashimoto’s thyroiditis was not
associated with CLNM in the above test. However, when
these variables were included in multivariate logistic
regression models, multifocal and bilateral tumors were not
statistically significant predictors of CLNM (Table 2).
3.3. Complications, follow-up, and recurrence
Among 1555 cN0 patients, 97 cases (6.24%) had transient
hypoparathyroidism and only two patients (0.13%) hadTable 1 Independent variable c2 test for CLNM.
Independent
variable
CLNM c2
value
p
Positive Negative
Gender male 163 104 29.983 0.000
female 550 738
Age < 45 y 471 373 73.658 0.000
 45 y 242 469
Multifocal Positive 389 361 21.109 0.000
Negative 324 481
Extrathyroidal
extension
Positive 535 477 57.417 0.000
Negative 178 365
Size  1 cm 379 680 135.429 0.000
> 1 cm 334 162
Bilateral
carcinoma
Positive 272 232 19.784 0.000
Negative 441 610
Combined with
nodular
goiter
Positive 318 470 19.442 0.000
Negative 395 372
Combined with
adenoma
Positive 35 69 6.681 0.010
Negative 678 773
Combined with
lymphocytic
thyroiditis
Positive 262 345 2.90 0.089
Negative 451 497
CLNM Z cervical lymph node metastasis.permanent hypoparathyroidism. Recurrent laryngeal nerve
injury after thyroidectomy occurred in 14 patients (0.9%);
nine of those cases were transient and the remaining five
were permanent. The permanently recurrent laryngeal
nerve paralyses were caused by serious tumor invasion. For
the patients’ follow-ups, postsurgical thyroid function test
and ultrasound examination were performed every 3e6
months. When tumor recurrence was suspected, fine nee-
dle aspiration was performed for pathologic confirmation.
All patients adhered to follow-up for at least 5 years, and
many had a longer period of follow-up. During the period of
follow-up, ranging from 5 years to 10 years, 18 patients
(1.16%) were found with locoregional recurrence, but none
had distant metastasis or died (Table 3).
4. Discussion
4.1. Risk factors for CLNM
During multivariate logistic regression analysis, we found
that male gender, young age ( 45 years of age), the
presence of ETE, and a primary tumor size > 10 mm were
risk factors of CLNM (odds ratio of 2.089, 2.417, 1.534, and
3.079, respectively). In a retrospective study, Jung et al5
indicated that risk factors for CLNM including age < 45
years, tumor size of  1 cm, and ETE predicted lymph node
metastasis. Randolph et al6 reported that tumor size,
number of metastatic lymph nodes, and presence of
extranodal extension of the tumor were correlated with
CLNM. Moreover, Lim et al7 reported that besides tumor
diameter, the number of central lymph nodes also belong as
risk factors for CLNM, predicting the prognosis of PTC pa-
tients. In our study, the positive rate of CLNM was up to
45.85% among patients with clinically negative lymph node
metastasis. We suggest that surgeons should not make a
decision for CLND only according to the T-stage of the
tumor. Meanwhile, many risk factors for CLNM, such as male
gender, young age ( 45 years of age), the presence of ETE,
and a primary tumor size > 10 mm should be also consid-
ered. Therefore, as for making a decision for CLND, a
pathological examination of FS during operation is
necessary.
There is an increased incidence of PTC in patients with
Hashimoto’s thyroiditis, implying the presence of more
than an incidental association between these two diseases.
Table 3 The characteristics of recurrent cases.
Patient ID Age/
Sex
Max Tumor
size (cm)
ETE Multifocality/
No. of foci
Tumor
bilaterality
Stage
by TNM
CLNR CLNM Postablation
sTg (mg/L)
Time to
recurrence
(mo)
BRAFV600E
mutation
Site of
locoregional
recurrence
1 54/F 2.3 þ  þ III 5/6 þ 12.1 32 þ Ipsilateral lateral
2 42/F 4.2 þ þ/2 þ I 3/4 þ 11.3 26 þ Contralateral
central
3 29/F 0.6    I 5/5 þ a 56 þ Ipsilateral lateral
4 37/M 0.9   þ I 3/6 þ 6.1 11 þ Bilateral central
5 77/F 1.3  þ/2 þ III 8/9 þ 9.3 17 þ Contralateral lateral
6 59/F 1.6  þ/3 þ IV 7/12 þ 22.8 47 þ Ipsilateral lateral
7 42/F 1.7    I 4/4 þ 4.9 32 þ Ipsilateral lateral
8 44/F 1.1   þ I 4/8 þ 3.2 38 þ Bilateral central
9 57/F 1.0   þ III 2/5 þ 5.1 24 þ Ipsilateral lateral
10 63/F 0.1    III 6/17 þ a 58 þ Contralateral lobe
and central
11 18/F 0.6    I 3/5 þ a 22 þ Contralateral lobe
and central
12 38/M 0.9 þ  þ I 4/6 þ 7.6 48 þ Ipsilateral lateral
13 67/F 2.1 þ þ/4 þ III 8/9 þ 46.8 44 þ Ipsilateral central
and lateral
14 68/F 1.3 þ   III 7/11 þ 5.7 25 þ Contralateral
central
15 59/M 0.7  þ/2 þ III 5/8 þ 12.9 48 þ Ipsilateral central
and lateral
16 71/F 0.9  þ/7 þ III 7/9 þ 33.9 10 þ Ipsilateral central
17 48/F 1.4 þ þ/4 þ IV 9/11 þ 21.5 26 þ Ipsilateral lateral
18 66/F 0.6  þ/5 þ III 2/4 þ 8.8 61 þ Ipsilateral lateral
CLNM Z central lymph node metastasis; CLNR Z central lymph node ratio; ETE Z extrathyroid extension.
a Case did not receive Iodine-131 ablation.
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Prophylactic CLND in cN0 PTC 135Accordingly, Hashimoto’s thyroiditis may be considered as a
precursor of PTC.8,9 However, the positive rate of Hashi-
moto’s thyroiditis is up to 39.04% among the 1555 PTC pa-
tients in our study. We found that the presence of
Hashimoto’s thyroiditis was not associated with CLNM
(p Z 0.089 > 0.05; Table 1).
4.2. Prophylactic CLND
At present, there is an argument regarding the necessity of
routine prophylactic CLND. Some surgeons advocate that
prophylactic CLND could not only provide a grading basis for
the prognosis of patients, postoperative treatment, and
follow-up of Iodine-131, but also reduce the thyroglobulin
levels after operation. It has been reported that a high
proportion (40e80%) of cN0 patients were changed to
clinically positive after CLND, similar to our findings
(45.85%).10 But, some scholars still believed, even without
CLND, the prognosis of PTC remains good. In addition, those
scholars also believed that CLND is more prone to causing
permanent hypoparathyroidism. However, in terms of the
high incidence rate of CLNM in PTC patients, we believe
that routine prophylactic CLND is very important in treating
PTC patients. An evaluation of PTC patients, mainly based
on the pathological examination of FS during operation,
also including many risk factors for CLNM, might be essen-
tial to CLND. Furthermore, in our study, among 1555 cN0
patients, 97 cases (6.24%) had transient hypoparathyroid-
ism and only two patients (0.13%) had permanent hypo-
parathyroidism. Those results suggest that, with advanced
surgery devices, the complication rate, such as permanent
hypoparathyroidism after operation was much lower than
that previously observed. Moreover, performance of CLND
also can reduce the recurrence rate near the recurrent
laryngeal nerve and the morbidity rate of the follow-up
surgery. In our study, among 1555 cN0 patients receiving
prophylactic CLND, only 18 patients (1.16%) had locore-
gional recurrence, but none had distant metastasis or were
deceased. Therefore, we support the opinion that routine
prophylactic CLND should be performed in cN0 PTC pa-
tients, because the second operation after recurrence not
only causes higher complication rates, but also increases
unnecessary economic and psychological burden to
patients.
4.3. Locoregional recurrence
The locoregional recurrence rate is 1.16% in our study,
which was lower than that reported in other papers,
especially for cN0 PTC patients.11e13 Prophylactic CLND
could decrease locoregional recurrence, because of the
removal of a large proportion of the occult positive central
lymph nodes. In our study, the characteristics of recurrent
cases as shown in Table 3 suggested that ipsilateral lateral
lymph node was the most vulnerable region of recurrence.
Many studies suggested that many factors, such as gender
(male), tumor size, bilaterality, extrathyroid extension,
lymph node metastasis, vascular invasion, and postablation
sTg were associated with locoregional recurrence.11e15
However, in our study, we did not perform statistical ana-
lyses to study the risk factors for recurrence in terms of thefewer recurrent cases (only 18 cases). According to the
characteristics of recurrent cases as shown in Table 3, we
found that three factors including positive CLNM, post-
ablation sTg  1 mg/L and BRAFV600E mutation were the
possible risk factors for recurrence, because those three
factors are all positive in recurrent cases. We need a large
randomized controlled trial and longer period follow-up to
ascertain risk factors of recurrence for cN0 patients with
prophylactic CLND.
5. Conclusion
Taken together, in terms of the high incidence rate of CLNM
in cN0 PTC patients, we believe that routine prophylactic
CLND is optimal for cN0 PTC patients during their first
treatment, especially for those with risk factors for CLNM.
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